8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Apr 27, 2026·SEC
Material company update
Mar 25, 2026·SEC
Terns Pharmaceuticals maintains a pre-revenue profile characterized by consistent R&D spending, averaging $18.5 million per quarter over the last ten quarters to advance its small-molecule pipeline. While the company's $524.7 million cash position provides a s...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q2 2026Latest May 14, 2026 | -$0.26+13.3% vs -$0.30 | — vs — |
Q2 2026 Apr 2, 2026 | -$0.25+13.8% vs -$0.29 | — vs — |
Q2 2026 Mar 30, 2026 | -$0.25+13.8% vs -$0.29 | — vs — |
Q4 2025 Nov 10, 2025 | -$0.27+10.0% vs -$0.30 | — vs — |
Benchmark TERN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Terns Pharmaceuticals, Inc. (TERN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $52.95 | $4.77B | -51.41 | — | — | -14.23% | — | |
| $513.02 | $11.83B | -39.92 | 432.05% | -25.32% | -56.65% | — | |
| $54.65 | $4.5B | -14.57 | — | — | -30.58% | — | |
| $28.39 | $6.33B | 55.67 | 59% | -5.51% | -30.03% | — | |
| $46.09 | $3.29B | -25.19 | — | — | -18.55% | — | |
| $35.95 | $2.07B | -14.98 | — | — | -16.91% | — |
Terns Pharmaceuticals, Inc. (TERN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Terns Pharmaceuticals, Inc. (TERN) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 5, 2026·SEC
Apr 27, 2026·SEC
Mar 25, 2026·SEC
Get notified when TERN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Terns Pharmaceuticals, Inc. (TERN) stock FAQ — growth, dividends, profitability & financials explained
Terns Pharmaceuticals, Inc. (TERN) reported a net loss of $96.2M for fiscal year 2025.
Terns Pharmaceuticals, Inc. (TERN) has a return on equity (ROE) of -14.2%. Negative ROE indicates the company is unprofitable.
Terns Pharmaceuticals, Inc. (TERN) had negative free cash flow of $82.2M in fiscal year 2025, likely due to heavy capital investments.